US 6444640B1
· Nagane et al.
· 2002
[cited by applicant]
US 6461823B1
· Ni et al.
· 2002
[cited by applicant]
US 6469144B1
· Ashkenazi
· 2002
[cited by applicant]
US 6521228B1
· Wiley et al.
· 2003
[cited by applicant]
US 6740739B1
· Ashkenazi et al.
· 2004
[cited by applicant]
US 6872568B1
· Ni et al.
· 2005
[cited by applicant]
US 7064189B2
· Salcedo et al.
· 2006
[cited by applicant]
US 7704502B2
· Zhou et al.
· 2010
[cited by applicant]
US 7736637B2
· Wiley et al.
· 2010
[cited by applicant]
US 7740847B2
· Allan et al.
· 2010
[cited by applicant]
US 9127070B2
· Ohtsuka et al.
· 2015
[cited by applicant]
US 20020155109A1
· Lynch
· 2002
[cited by applicant]
US 20040019915A1
· Challita-Eid et al.
· 2004
[cited by applicant]
US 20040141982A1
· Lust et al.
· 2004
[cited by applicant]
US 20040147725A1
· Chuntharapai et al.
· 2004
[cited by applicant]
US 20040167319A1
· Teeling et al.
· 2004
[cited by applicant]
US 20050233958A1
· Ni et al.
· 2005
[cited by applicant]
US 20050244857A1
· Ni et al.
· 2005
[cited by applicant]
US 20050266008A1
· Graziano et al.
· 2005
[cited by applicant]
US 20070026000A1
· Ashkenazi et al.
· 2007
[cited by applicant]
US 20080248037A1
· Li et al.
· 2008
[cited by applicant]
US 20090013117A1
· Huang
· 2009
[cited by applicant]
US 20090022707A1
· Kimberly et al.
· 2009
[cited by applicant]
US 20150353636A1
· Parren et al.
· 2015
[cited by applicant]
US 20190144554A1
· Overdijk et al.
· 2019
[cited by applicant]
US 20190202926A1
· Beurskens et al.
· 2019
[cited by applicant]
US 20190276549A1
· De Jong et al.
· 2019
[cited by applicant]
US 20210230301A1
· De Jong et al.
· 2021
[cited by applicant]
US 20220411522A1
· Beurskens et al.
· 2022
[cited by applicant]
US 20230107363A1
· De Jong et al.
· 2023
[cited by applicant]
CA 2878790A1
· 2014
[cited by applicant]
WO 2008004760A1
· 2008
[cited by applicant]
WO 2010003766A2
· 2010
[cited by applicant]
WO 2013004842A2
· 2013
[cited by applicant]
WO 2014006217A1
· 2014
[cited by applicant]
WO 2014009358A1
· 2014
[cited by applicant]
WO 2014108198A1
· 2014
[cited by applicant]
WO 2017093447A1
· 2017
[cited by applicant]
WO 2017093448A1
· 2017
[cited by applicant]
Tse et al., Indomethacin Sensitizes TRAIL-Resistant Melanoma Cells to TRAIL-Induced Apoptosis through ROS-Mediated Upregulation of Death Receptor 5 and Downregulation of Survivin, J. Invest. Dermatol. 134:1397-1407,2014.
[cited by examiner]
Janeway et al., Immunology Third Edition, Garland Publishing Inc. 1997, Chapter 3, Structure of the Antibody Molecule and Immunoglobulin Genes, pp. 3:1-3:11. (1997).
[cited by applicant]
Amminmaki, U. et al., “Crystal structure of a recombinant anti-estradiol Fab complex with 17Beta-estradiol,” J. Biol. Chem., vol. 276(39):36687-36694 (2001).
[cited by applicant]
MacFarlane, M., “Death receptors at the molecular level: therapeutic implications,” Cell Death, pp. 117-126 (2010).
[cited by applicant]
Qiu, Y. et al., “A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth,” IU BMB Life, vol. 64(9):757-765 (2012).
[cited by applicant]
Sadarangani, A. et al., “TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.,” Apoptosis, vol. 12(1):73-85 (2007).
[cited by applicant]
Secchiero, P. et al., “Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minbody with anti-leukimeic activity,” Int. J.Innnnunopathol. Pharmacol., vol. 22(1):73-83 (2009).
[cited by applicant]
Pan, G. et al., “An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL,” Science, vol. 277 (5327):815-818 (1997).
[cited by applicant]
Parren P. Targeting cell surface antigens with a novel therapeutic antibody concept, Peptalk.
[cited by applicant]
Parren, P. et al., “Functional aspects and therapeutic application of antigen- and Fc-dependent formation of IgG hexamers at the cell surface,” Keystone symposium “Antibodies as Drugs” Whistler, Canada, Mar. 7, 2016, 33…
[cited by applicant]
Plummer, R. et al., “Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers,” Clin Cancer Res., vol. 30 (13):6187-6194 (2007).
[cited by applicant]
Reddy, A. et al., “Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages,” PLoS One, vol. 10(9): e0138486 (2015).
[cited by applicant]
Rowinsky, E., “Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents,” J Clin Oncol., vol. 23(36):9394-9407 (2005).
[cited by applicant]
Schuurman, J. et al., “Functional Aspects of Antigen- and Fc-Dependent IgG Hexamer Formation,” PEGS EU, Nov. 3, 2016, Lisbon, Portugal.
[cited by applicant]
Sessler, T. et al., “Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signaling,” Pharmacol Ther., vol. 140(2):186-199 (2013).
[cited by applicant]
Sheridan, J., et al., “Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors,” Science, vol. 277 (5327): 818-821 (1997).
[cited by applicant]
Spierings, D. et al., “Tissue Distribution of the Death Ligand TRAIL and Its Receptors,” Journal of Histochemistry & Cytochemistry, vol. 52(6): 821-831 (2004).
[cited by applicant]
Trivedi, R., et al., “Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells,” Front Oncol., vol. 5 (69):20 pages (2015).
[cited by applicant]
Twomey, J. et al., “Spatial dynamics of TRAIL death receptors in cancer cells,” Drug Resist Updat., vol. 19:13-21 (2015).
[cited by applicant]
Valley, C. et al., “Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Death Receptor 5 Networks That are Highly Organized,” J Biol Chem., vol. 287(25):21265-21278 (2012).
[cited by applicant]
Vermot-Desroches C. et al., “Characterization of monoclonal antibodies directed against trail or trail receptors,” Cellular Immunology, vol. 236 (1-2): 86-91 (2005).
[cited by applicant]
Wakelee, H.A et al., “Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors,” Annals of Oncology, vol. 21, Issue 2:376-381 (2010).
[cited by applicant]
Walczak, H. et al., “Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo,” Nature Medicine., vol. 5:157-163 (1999).
[cited by applicant]
Wall J. et al., “AMG 655, a monoclonal antibody agonist directed against Death Receptor 5, induces apoptosis in human colon carcinoma cell lines and its therapeutic potential is enhanced in combination with chemotherape…
[cited by applicant]
Wang, et al., “Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis,” Cellular & Molecular Immunology, vol. 5: 55-60 (2008).
[cited by applicant]
Wartha, K. et al., “A novel bispecific Fap-Dr5 antibody inducing potent and tumor-specific death receptor 5 (Dr5) activation by fibroblast activation protein (Fap)-dependent crosslinking,” Abstract 4573, Proceedings of …
[cited by applicant]
Wassenaar, T. et al., “The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study,” Protein, vol. 70(2):333-343 (2008).
[cited by applicant]
Wiley, S.R. et al., “Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis,” Immunity, vol. 3:673-682 (1995).
[cited by applicant]
Wolf, E. et al., “Monoclonal antibody homodimers: enhanced antitumor activity in nude mice,” Cancer Research, vol. 53(11):2560-2565 (1993).
[cited by applicant]
Yano, S. et al., “Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition,” Anticancer Res., vol. 23:3629-3650 (2003).
[cited by applicant]
Zhang, X. et al., “Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types,” FEBS Letters, vol. 482: 193-199 (2000).
[cited by applicant]
Adams, C., et al., “Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5,” Cell Death & Differentiation, vol. 15 : 751-761(2008).
[cited by applicant]
Amgen Inc., “A phase Ib study to evaluate the safety and tolerability of AMG 655 in combination with bortezomib or vorinostat in subjects with relapsed or refractory lymphoma,” Public Results Redacted CSR Synopsis, Abbr…
[cited by applicant]
Ashkenazi, A. et al., “Directing cancer cells to self-destruct with pro-apoptotic receptor agonists,” Nat Rev Drug Discov., vol. 7(12):1001-1012 (2008).
[cited by applicant]
Ashkenazi, A. et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand,” J Clin Invest., vol. 104(2):155-162 (1999).
[cited by applicant]
Beurskens, F. et al., “Functional aspects of antigen- and Fc-dependent IgG hexamer formation,” Antibody Biology & Engineering Gordon Research Conference, Mar. 22, 2016 Galveston, TX, 15 pages.
[cited by applicant]
Breij, E. et al., “Functional aspects and therapeutic application of antigen-dependent formation of IgG hexamers at the cell surface,” IBC Antibody Engineering & Therapeutics 2015, Dec. 7, 2015 San Diego, 25 pages.
[cited by applicant]
Buchsbaum DJ et al., “Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model1,” Cancer Res., vol. 9:3731-3734 (2003).
[cited by applicant]
Buchsbaum DJ et al., “TRAIL receptor-targeted therapy,” Future Oncol., vol. 2(4):493-508 (2006).
[cited by applicant]
Chen, C. et al., “Enhancement and destruction of antibody function by somatic mutation:unequal occurrence is controlled by V gene combinatorial associations,” EMBO J., vol. 14(12):2784-2794 (1995).
[cited by applicant]
Chinnaiyan, A.M., et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy,” PNAS, vol. 97(4):1754-1759 (2000).
[cited by applicant]
Daniel PT et al., “Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells,” J Immunol., vol. 152 (12) 5624-5632 (1994).
[cited by applicant]
De Jong, R. et al., “A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface,” PLOS Biology, vol. 14 (1): e1002344 (2016).
[cited by applicant]
De Jong, R. et al., Improving therapeutic activity of agonistic DR5 antibodies by inducing target binding-dependent hexamer formation, PEGS DR 5, 1 page (2016).
[cited by applicant]
De Jong, R. et al., “Therapeutic antibody potentiation by antigen- and Fc-dependent IgG hexamer formation,” MipTec International Life Science Exhibition Session Biotherapeutics—Current challenges in protein science, Sep…
[cited by applicant]
Derosier, L. et al., “Combination Treatment with TRA-8 Anti-Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer,” Clin Cancer Res., vol. 13(18 Pt2) 5535s-5543s (2007…
[cited by applicant]
Derosier, L. et al., “TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth,” Mol Cancer Ther., vol. 6(12 Pt 1):3198-3207 (2007).
[cited by applicant]
Fox N.L. et al. “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy,” Exper Opin Biol Ther., vol. 5(10):1-18 (2010).
[cited by applicant]
Friess, T. et al., “Induction of avidity-driven hyperclustering of DR5 by a new FAP-DR5 bispecific antibody (RG7386) eads to strong antitumor efficacy,” Abstract 952:, AACR 106th Annual Meeting 2015; Apr. 18-22, 2015; P…
[cited by applicant]
Georgakis GV et al., “Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubic…
[cited by applicant]
Gieffers, C. et al., “APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fc? receptors,” Mol Cancer Ther., vol. 12(12): 2735-2747 (2013).
[cited by applicant]
Gura, T. et al., “How TRAIL Kills Cancer Cells, But Not Normal Cells,” Science, vol. 277 (5327) 7 pages (1997).
[cited by applicant]
Herbst R.S. e al., “A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an poptosis-inducing protein in patients with advanced cancer,” Abstract No. 3013, J Clin Oncol., vol. 24, 6 pages (2006).
[cited by applicant]
Herbst, R. et al., “A first-in-human study of Conatumumab in adult patients with advanced solid tumors,” Clin. Canc. Res., vol. 16(23):5883-5891 (2010).
[cited by applicant]
Hibbert, R., “From biology to technology: the HexaBody® platform,” BPI Europe 2016, 27 pages.
[cited by applicant]
Holland, P. et al., “Death receptor agonist therapies for cancer, which is the right TRAIL?,” Cytokine Growth Factor Rev., vol. 25(2):185-193 (2014).
[cited by applicant]
Hotte, S.J. et al., “A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies,” Clin Cancer Res., vol. 14(11):3450-3455 (2008).
[cited by applicant]
Huet, H. et al., “Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction,” MAbs, vol. 6(6):1560-1570 (2014).
[cited by applicant]
Hymowitz, S. et al., “Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5,” Mol Cell., vol. 4(4):563-71 (1999).
[cited by applicant]
Ichikawa K. et al., “Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity,” Nat. Med., vol. 7(8):954-960 (2001).
[cited by applicant]
International Preliminary Report on Patentability, PCT/EP2013/064466, dated Jan. 13, 2015, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/EP2016/079517, dated Jun. 5, 2018, 13 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/EP2016/079518, dated Jun. 5, 2018, 14 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/EP2013/064466, dated Sep. 30, 2013, 10 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/EP2016/079517, dated Mar. 31, 2017, 19 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/EP2016/079518, dated Mar. 31, 2017, 21 pages.
[cited by applicant]
Kaplan-Lefko, P. et al., “AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model,” AACR Annual Meeting—Apr. 12-16, 2…
[cited by applicant]
Lamminmaki, U. et al., “Crystal structure of a recombinant anti-estradiol Fab complex with 17Beta-estradiol,” J. Biol. Chem., vol. 276(39):36687-36694 (2001).
[cited by applicant]
Li J. et al.,, “Antitumor efficacy of LBY135, an anti-DR5 monoclonal antibody, alone or in combination with chemotherapy in human colon tumor cell lines and xenografts, ” AACR Annual Meeting—Apr. 14-18, 2007; Los Angele…
[cited by applicant]
Li, J. et al., “DART® molecules with enhanced DR5 agonistic activity for improved cancer cell Cytotoxicity,” Abstract 2464, AACR 106th Annual Meeting 2015, Apr. 18-22, 2015 Philadelphia, PA, 4 pages (2015).
[cited by applicant]
Lim, B. et al., “Targeting TRAIL in the treatment of cancer: new developments,” Expert Opin Ther Targets, vol. 19(9):1171-1185 (2015).
[cited by applicant]
Liu, F. et al., “The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells,” Biome Pharmacother., vol. 70:41-45 (2015).
[cited by applicant]
Long JW. et al., “TRA-8 (TRAIL-R2 Antibody) Based Combination Chemotherapy Produces a Survival Benefit in a Pancreatic Cancer Orthotopic Model,” Abstract 40, J Virg Res., vol. 37:167 (2007).
[cited by applicant]
MacCallum, R. et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J. Mol. Blol., vol. 262:732-745. (1996).
[cited by applicant]
MacFarlane, M., “Death receptors at the molecular level: therapeutic implications, in Cell Death,” Melino and Vaux, Eds., John Wiley & Sons: Singapore, pp. 117, 136 (2010).
[cited by applicant]
Marini P. et al., “Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo,” Oncogene, …
[cited by applicant]
Milenic, D. et al., “Construction, Binding Properties, Metabolism, and Tumor Targeting of a Single-Chain Fv Derived from the Pancarcinoma Monoclonal Antibody CC49,” Cancer Res., vol. 51:6363-6371 (1991).
[cited by applicant]
Nagane, M. et al., “Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo,” Neuro-Oncology, vol. 12(7): 687-700 (2010).
[cited by applicant]
Oliver, PG et al., “Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11,” Clin Cancer Res., vol. 14(7):2180-2189 (2008).
[cited by applicant]
Overdijk, M. et al., “Improving therapeutic activity of agonistic DR5 antibodies by inducing target binding-dependent hexamer formation,” Abstract No. 592 , AACR DR5, 1 page (2016).
[cited by applicant]
U.S. Appl. No. 18/744,540, filed Jun. 14, 2024, Paul Parren.
[cited by applicant]